You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs i ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Drug regulators of nitric oxide production as Alzheimer's disease therapeutics

    SBC: Epigen Biosciences, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Druggable regulators of nitric oxide production as new Alzheimer's disease therapeutics Summary: Nitrosative stress is a critical mediator of the onset and progression of Alzheimer's disease (AD): it precedes and is associated with neuritic dystrophy and dendritic spine loss, A /amyloid accumulation and deposition, cholinergic denervation and a memory ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. The Memory Care Navigator: A Proactive Guide

    SBC: Proactive Memory Services            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is an irreversible neurological disease that progressively causes a tremendous toll in disability and societal cost. As our population ages, AD and other memory disorders will become increasingly prevalent. Patients and their families often find themselves lost in a complex web of multiple providers, receiving conflicting recommend ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Point-of-Care Diagnostic Test for Entamoeba histolytica Cysts

    SBC: TECHLAB, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The NIAID Category B priority pathogen Entamoeba histolytica is a public health threat, especially as a cause of diarrhea in travelers to and immigrants from endemic areas, men who have sex with men, and children in thedeveloping world where it is in the top 5 causes of severe diarrhea. It is also a biodefense threat to water and food supplies due to its resist ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. A novel vaccine against vaginal Chlamydia trachomatis

    SBC: EPITOGENESIS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Treating EAE disease with Fc-Dimers

    SBC: LeukoSight Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): We have developed a recombinant polypeptide that we have termed Fc-Dimers (Di -mers). This product has potent anti-inflammatory activity in vitro, and we propose to test this reagent in an animal model of autoimmunedisease. We have selected the murine disease, Experimental Autoimmune Encephalomyelitis (EAE), a model for human multiple sclerosis (MS). Pathol ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Redesign of the Carbapenem Scaffold

    SBC: THERAVANCE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Carbapenemase-producing bacteria now threaten to undermine the efficacy of the carbapenems, long considered to be the most potent and reliable of the -lactam antibiotics. In Gram-negative microorganisms, in particular,the ability to produce class A serine carbapenemases, such as the plasmid-mediated KPC enzymes, or class B metallo-carbapenemases, such as the ND ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a diagnostic biomarker for Ewing's Sarcoma family of tumors.

    SBC: Entrogen, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Development of a diagnostic biomarker for Ewing's Sarcoma family of tumors Ewing's family tumors (EFTs) are characterized by recurrent chromosomal translocations that produce chimeric fusions between the EWS gene and one of five ETS transcription factors. The expression of EWS/FLI1, the predominant fusion product in EFTs, is believed to deregulate do ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Imaging Mass Spectroscopy for Biomarker Detection in Human Tissues

    SBC: PROVIA BIOLOGICS LIMITED LIABILITY COMPANY            Topic: NCI

    DESCRIPTION (provided by applicant): Biomarkers are measured in patient tissue biopsies to refine diagnosis, and to guide therapy. For a patient, this means receiving the therapy or drug most likely to work while avoiding the expense and toxic side effectsof alternatives. In pathology, a long-standing problem is that the most accurate methods for biomarker detection in tissues require extraction a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. A novel diagnostic test for Irinotecan and Topotecan sensitivity

    SBC: RG Biopharma            Topic: NCI

    DESCRIPTION (provided by applicant): The long term objective of this Phase 1 study is to produce an antibody-based diagnostic assay to detect tumor responsiveness to a widely used class of chemotherapeutic agents derived from camptothecin that includes Irinotecan and Topotecan. The assay will be based on a novel biomarker associated with cellular sensitivity to camptothecin and will have clinical ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government